Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.
Fiche publication
Date publication
juin 2022
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal, Pr ENTZ-WERLE Natacha
Tous les auteurs :
Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, André N, Ciccolini J
Lien Pubmed
Résumé
Better understanding of pharmacokinetics of oral vinorelbine (VNR) in children would help predicting drug exposure and, beyond, clinical outcome. Here, we have characterized the population pharmacokinetics of oral VNR and studied the factors likely to explain the variability observed in VNR exposure among young patients.
Mots clés
ABCB1, P-glycoprotein, Pediatric drug development, Population pharmacokinetic analysis, Vinorelbine
Référence
Cancer Chemother Pharmacol. 2022 06 25;: